Which pill works best for postpartum high blood pressure? small study aims to find out.

NCT ID NCT05049616

Completed Disease control Sponsor: The University of Texas Health Science Center, Houston Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested two common blood pressure medications—a combination pill of hydrochlorothiazide and lisinopril versus extended-release nifedipine—in 70 new mothers with high blood pressure after delivery. The goal was to see which pill controls blood pressure better in the first week and a half after childbirth. Both drugs are already used in standard care, so this study aims to refine treatment choices rather than discover a new therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydrochlorothiazide/Lisinopril (Zestoretic) and extended-release nifedipine
What this could lead to: If it works, this could point toward a better first-choice pill for managing high blood pressure after childbirth.
What could go wrong: This is a small pilot study with only 70 participants, so results may not apply to all women. Both drugs are already used in standard care, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced hypertensive disorder preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION IN PREGNANCY POSTPARTUM PREECLAMPSIA

Contacts and locations

Locations

University of Texas Health Science Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.